Reprogramming Chronic Neuropathic Pain Signals...

Through non-invasive, information-based neuromodulation.

Implemented in Academic and Clinical Settings Worldwide

*Institutional logos represent sites where Scrambler Therapy® has been used in clinical or research settings. Inclusion does not imply institutional endorsement.

Rethinking the Paradigm of Chronic Pain Treatment

What is Scrambler Therapy?

Scrambler Therapy® is a non-invasive neuromodulation therapy for chronic neuropathic pain based on information substitution rather than signal inhibition. By delivering synthetic non-pain information through surface receptors, the therapy is designed to replace maladaptive pain signaling rather than block or gate it through inhibitory mechanisms.

The Scrambler Therapy^® Advantage

How It Works

Scrambler Therapy® does not damage tissue, implant hardware, or rely on ongoing inhibition of nerve activity. Instead, it represents a signal-based neuromodulation strategy designed to address chronic neuropathic pain by modifying the information driving it.

100% Non-Invasive Neuromodulation

Delivered transcutaneously using surface electrodes, with no implants, injections, or tissue ablation.

Information-Based Signal Substitution

Designed to replace maladaptive pain information rather than suppress transmission through inhibitory or gating mechanisms.

Targets Central Pain Processing

Aims to influence how pain is interpreted and maintained at the central nervous system level, not only peripheral transmission.

Utilizes Structured Synthetic Signaling

Employs engineered non-pain signal sequences intended to be recognizable by the nervous system as physiologic information.

Clinician-Administered and Protocol-Driven

Requires formal training and certification to ensure appropriate electrode placement and treatment delivery.

Short Treatment Course with Long-Lasting Clinical Benefit

Clinical studies report that a short treatment course, typically completed within one to two weeks, can result in pain relief lasting months to years in many patients.

The Evidence Base

Clinical Evidence & Published Research

Scrambler Therapy® is supported by over 90 clinical publications, including peer-reviewed studies in leading medical journals. Published outcomes across multiple neuropathic pain conditions have reported response rates of approximately 80–90%, alongside a favorable safety profile with no device-related adverse events reported over more than 20 years of clinical use and tens of thousands of treated patients.

Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain

Authors: Thomas J. Smith, M.D., Eric J. Wang, M.D., and Charles L. Loprinzi, M.D.

Published July 12, 2023

DOI: 10.1056/NEJMra2110098

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial

Authors: Giuseppe Marineo, Vittorio Iorno, Cristiano Gandini, Vincenzo Moschini, Thomas J Smith

Published July 16, 2011

DOI: 10.1016/j.jpainsymman.2011.03.015

The Impact of Scrambler Therapy on Pain and Quality of Life for Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study

Authors: Matthew Chung, Tsun Hsuan Chen, Xin Shelley Wang, Kyung-Hoon Kim, Salahadin Abdi

Published February 28, 2024

DOI: 10.1111/papr.13355

BACKED BY RESEARCH - PROVEN BY PATIENTS

Consult With Our Clinical Specialists Today

Connect With Our Team

Last updated on February 26, 2026

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Scrambler Therapy® is intended for the non-invasive treatment of chronic neuropathic pain through transcutaneous electrical stimulation designed to provide symptomatic relief of pain. Scrambler Therapy® should only be administered by individuals who have completed authorized Scrambler Therapy® training and certification, and its use should be guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of indications, contraindications, warnings, and precautions.

Footer last updated on February 26, 2026